How to assist biological therapy after kidney cancer surgery

About 10% of patients with renal cancer will experience spontaneous regression of metastatic lesions after surgery. Therefore, some scholars believe that renal cancer is an immunogenic tumor. In 1985, Rosenberg et al. in the United States first confirmed that lymphokine-activated killer cells plus interleukin-2 (IL-2) were effective in treating advanced renal cancer, and subsequently conducted a series of clinical studies on adjuvant biological therapy after renal cancer surgery.

Adjuvant interferon therapy after renal cell carcinoma surgery In 2001, Pizzocaro et al. reported the results of a multicenter randomized controlled study on adjuvant interferon Ⅸ 2b (interferonalfa-2b, IFN-a2b) therapy for patients with renal cell carcinoma after surgery.

Adjuvant IL-2 therapy after renal cancer surgery In 2003, Clark et al. reported the results of a prospective, randomized, controlled phase III clinical study on the use of high-dose interleukin-2 (HDIL-2) as adjuvant therapy after surgery for high-risk renal cancer patients.

In 1996, the results of a clinical study on the use of autologous tumor cell vaccine Bacillus Calmette-Guerin (BCG) as an adjuvant therapy for renal cancer patients after surgery were reported.